Immune Related Adverse Events - Toxicology

Relevant Publications

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort.

Issue Release: 2024

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.

Issue Release: 2024

Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.

Issue Release: 2024

Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institution.

Issue Release: 2024

Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.

Issue Release: 2024

Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by F-BMS986-192 PET: pooled analysis of data from four solid tumor types.

Issue Release: 2024

A comprehensive supportive care program for fine-tuning cancer immunotherapy.

Issue Release: 2024

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.

Issue Release: 2024

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study.

Issue Release: 2024

Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis.

Issue Release: 2024

Analysis of clinical characteristics and prognosis of lung cancer patients with CPFE or COPD: a retrospective study.

Issue Release: 2024

Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.

Issue Release: 2024

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.

Issue Release: 2024

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.

Issue Release: 2024

Changing the location of proteins on the cell surface is a promising strategy for modulating T cell functions.

Issue Release: 2024

A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial).

Issue Release: 2024

Integrating Chinese medicine into mainstream cancer therapies: a promising future.

Issue Release: 2024

Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma.

Issue Release: 2024

Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors.

Issue Release: 2024

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update.

Issue Release: 2024

How Do You Select the Right PAPR for Toxicological Work?

What Are the Risks of Drug Accumulation?

Why is Data Interpretation Important?

Can Supplements Help Boost the Immune System?

What is Homeostasis in the Context of Toxicology?

Why is Species Consideration Important in Toxicology?

How Do We Approach Risk Assessment?

What Are the Future Directions in Nano-sized Particle Toxicology?

What is the Role of Toxicologists in Insulin Overdose Cases?

What is Personalized Toxicology?

Immune Related Adverse Events - Toxicology

Relevant Publications

Partnered Content Networks

Relevant Topics